1. Improving affordability of new Essential Cancer Medicines

   t'Hoen, E., Meyer, S., Durisch, P., Bannenberg, W., Perehudoff, K., Reed, T. & Barber, M. J., Aug-2019, In : Lancet Oncology. 20, 8, p. 1052-1054 4 p.

   Research output: Contribution to journal › Editorial › Academic › peer-review

2. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial

   FaMRIsc Study Grp, Saadatmand, S., Geuzinge, H. A., Rutgers, E. J. T., Mann, R. M., van Zuidewijn, D. B. W. D. R., Zonderland, H. M., Tollenaar, R. A. E. M., Lobbes, M. B., Ausems, M. G. E. M., van t'Riet, M., Hooning, M. J., Mares-Engelberts, I., Luiten, E. J. T., Heijnsdijk, E. A. M., Verhoef, C., Karssemeijer, N., Oosterwijk, J. C., Obdeijn, I-M., de Koning, H. J. & Tilanus-Linthorst, M. M. A., Aug-2019, In : Lancet Oncology. 20, 8, p. 1136-1147 12 p.

   Research output: Contribution to journal › Article › Academic › peer-review

3. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

   Banerji, U., van Herpen, C. M. L., Saura, C., Thistiethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., Rottey, S., Geenen, J., Eskens, F., Gil-Martin, M., Mommers, E. C., Koper, N. P. & Aftimos, P., Aug-2019, In : Lancet Oncology. 20, 8, p. 1124-1135 12 p.

   Research output: Contribution to journal › Article › Academic › peer-review

4. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

   CheckMate 214 investigators, Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., Porta, C., George, S., Neiman, V., Bracarda, S., Tykodi, S. S., Barthélémy, P., Leibowitz-Amit, R., Plimack, E. R., Oosting, S. F., Redman, B., Melichar, B., Powles, T., Nathan, P., Oudard, S., Pook, D., Choueiri, T. K., Donskov, F., Grimm, M-O., Gurney, H., Heng, D. Y. C., Kollmannsberger, C. K., Harrison, M. R., Tomita, Y., Duran, I., Grünwald, V., McHenry, M. B., Mekan, S. & Tannir, N. M., Oct-2019, In : Lancet Oncology. 20, 10, p. 1370-1385 16 p.

   Research output: Contribution to journal › Article › Academic › peer-review

5. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

   PORTEC study group, de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., D'Amico, R., Fyles, A., Baron, M-H., Jürgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Gribaudo, S., Provencher, D., Hanzen, C., Kruitwagen, R. F., Smit, V. T. H. B. M., Singh, N., Do, V., Lissoni, A., Nout, R. A., Feeney, A., Verhoeven-Adema, K. W., Putter, H. & Creutzberg, C. L., Sep-2019, In : Lancet Oncology. 20, 9, p. 1273-1285 13 p.

   Research output: Contribution to journal › Article › Academic › peer-review

View all (74) »